

U alb/c at Baseline and Weeks 3, 4, 8, 12, 24, 30, 36, and 52 Following Conversion to SRL

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 3, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.46	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 3, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.05	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 4, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.43	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 4, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.37	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 8, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.67	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 8, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.74	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 12, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.91	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 12, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.92	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 24, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	ERROR: A poorly formatted P-Value has been entered.	
Method		
Other Adjusted Geometric Mean Fold Change	2.33	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 24, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	3.39	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 30, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.50	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 30, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	3.39	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 36, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.52	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 36, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	3.27	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 52, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	2.92	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 52, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	3.45	Adjusted for baseline